Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2028

Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
COMBINATION_PRODUCT

Extracorporeal Photopheresis (ECP)

"Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen"

OTHER

No intervention in the SOC / Retrospective Chart review.

SOC Retrospective chart review similar to a control group

Trial Locations (22)

10032

Columbia University, New York

15213

University of Pittsburgh, Pittsburgh

19140

Temple University, Philadelphia

22042

Inova Health System, Falls Church

27710

Duke University, Durham

32610

University of Florida, Gainesville

35226

University of Alabama at Birmingham, Birmingham

40506

University of Kentucky, Lexington

43210

Ohio State University, Columbus

45903

Spectrum Health, Grand Rapids

46202

Indiana University Health, Indianapolis

48109

University of Michigan Health System, Ann Arbor

52242

University of Iowa, Iowa City

55455

University of Minnesota Medical Center, Fairview, Minneapolis

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

75246

Baylor University Medical Center, Dallas

75390

UT Southwestern Medical Center, Dallas

77030

Houston Methodist, Houston

85013

St. Joseph's Hospital and Medical Center, Phoenix

92093

University of California San Diego, La Jolla

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Centers for Medicare and Medicaid Services/ Coverage and Analysis Group

FED

collaborator

Therakos, Inc

UNKNOWN

collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER